Treatment of hypertension with a fixed ratio combination of long-acting propranolol and bendrofluazide, and influence of age of the subject.
The efficacy of sustained-release propranolol 160 mg (Inderal LA), bendrofluazide 5 mg and the combination preparation Inderex (bendrofluazide 5 mg and Inderal LA) in the treatment of hypertension was investigated. Twenty-one patients over a wide age range were studied, as it was of particular interest to find whether differing responses across a range of age groups might exist 24 hours post-dosing. Blood pressure control was greater with Inderex than with either Inderal LA or bendrofluazide. No significant difference between different age groups on the three treatments was demonstrated. There was some evidence, not statistically significant, suggesting potassium values to be lower on bendrofluazide and on Inderex. Serum glutamate oxaloacetate transaminase (SGOT) values were raised on bendrofluazide. Inderex is more effective in lowering blood pressure than either bendrofluazide or Inderal LA alone, and as a single capsule given once daily encourages compliance in comparison with combination treatments.
Herrick
A L
AL
Davis
J M
JM
Weir
R J
RJ
D000328:Adult; D000367:Age Factors; D000368:Aged; D001219:Aspartate Aminotransferases; D001539:Bendroflumethiazide / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011187:Posture; D011433:Propranolol / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D001539:Bendroflumethiazide; D011433:Propranolol; D001219:Aspartate Aminotransferases